After a successful start, the group is breaking major news. Following lengthy and demanding preparation and negotiations, we can announce that clinical trials will be conducted on the premises of the Váš Lekár polyclinic in cooperation with an international pharmaceutical company. This is a milestone that significantly improves the project’s profitability profile – it brings a new, high-margin and stable source of revenue, strengthens the polyclinic's prestige and increases its attractiveness to both patients and partners.

What was covered during the webinar?

• CEO Peter Potúček (ex-Novartis, ŠÚKL) presented the individual businesses, vision and management plans of the Váš Lekár healthcare group
• Inclusion in a prestigious clinical trial with a global pharmaceutical corporation
• Current financial results, growth and plans of the group for the coming years
• Investment parameters, expected return and investment horizon
• Q&A

We will close the investment on January 30, 2026! After that, it will not be possible to express interest in investing.